This Phase I research study is for individuals with advanced melanoma or lymphoma. The purpose of this study is to determine and confirm the safety and tolerance of a drug called DS‐3032b at the maximum tolerated dose in the patients enrolled. Preliminary safety and tolerability has been established in Part 1 dose escalation, so Part 2 is to confirm those in the intended population. DS‐3032b is an investigational drug, taken as a capsule, designed to block MDM2‐p53 interaction (a molecular interaction that can help tumor growth).

The purpose of this study is to find out more about the effects of AMG 228 in people that have advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. AMG 228 is an experimental drug that is being developed to stimulate the body’s immune system to kill cancer cells. This study is the first to test AMG 228 in people. This study will look at what doses of AMG 228 are safe for people to take and whether it causes any side effects.

The primary purpose of this research study is to assess how safe and well tolerated the study drugs, INCB024360 and nivolumab, are when given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB024360 in combination with nivolumab works in preventing disease progression patients with melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer and diffuse large B cell lymphoma.

The primary purpose of this research study is to assess how safe and well tolerated the study drug, IDH305, is when given to patients who have advanced tumors that harbor IDH1R132 mutations. Pre-clinical data suggest the importance of these mutations in maintaining cancer. The hypothesis of this research study is inhibiting the mutant IDH1 mutation in these tumors will result in anti-tumor activity.

Prospective protocol assessing the safety of autologous blood transfusions following pancreatectomy for pancreatic ductal adenocarcinoma (PDAC)

Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be retrieved from the donor using current donor lung retrieval techniques.